Business Description
Regulus Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75915K1016
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.95 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 26.3 | |||||
3-Year EPS without NRI Growth Rate | 29.5 | |||||
3-Year FCF Growth Rate | 26.2 | |||||
3-Year Book Growth Rate | -35.3 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.26 | |||||
9-Day RSI | 42.78 | |||||
14-Day RSI | 46.85 | |||||
6-1 Month Momentum % | 125.64 | |||||
12-1 Month Momentum % | 118.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 3.31 | |||||
Cash Ratio | 2.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.2 | |||||
Shareholder Yield % | -7.88 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -104.78 | |||||
ROA % | -76.67 | |||||
ROIC % | -321.87 | |||||
ROC (Joel Greenblatt) % | -1188.5 | |||||
ROCE % | -97.84 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 2.31 | |||||
EV-to-EBIT | -4.66 | |||||
EV-to-EBITDA | -4.69 | |||||
EV-to-FCF | -5.01 | |||||
Price-to-Net-Current-Asset-Value | 2.63 | |||||
Price-to-Net-Cash | 3.47 | |||||
Earnings Yield (Greenblatt) % | -21.46 | |||||
FCF Yield % | -17.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Regulus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.467 | ||
Beta | 0.71 | ||
Volatility % | 107.29 | ||
14-Day RSI | 46.85 | ||
14-Day ATR (€) | 0.111928 | ||
20-Day SMA (€) | 2.303 | ||
12-1 Month Momentum % | 118.18 | ||
52-Week Range (€) | 1.01 - 2.78 | ||
Shares Outstanding (Mil) | 65.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Regulus Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Regulus Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Regulus Therapeutics Inc Frequently Asked Questions
What is Regulus Therapeutics Inc(STU:7RG0)'s stock price today?
When is next earnings date of Regulus Therapeutics Inc(STU:7RG0)?
Does Regulus Therapeutics Inc(STU:7RG0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |